Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBARK: tezepelumab in adults with moderate to very severe COPD
CTR20252904Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tezepelumab in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Sep 2025; status: active.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20252904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252904.